Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study
暂无分享,去创建一个
Jun Zhu | Roya Kelishadi | Salim Yusuf | Prem Mony | Andreas Wielgosz | Fernando Lanas | Patricio Lopez-Jaramillo | Rajeev Gupta | Omar Rahman | S. Yusuf | G. Dagenais | Jun Zhu | P. López-Jaramillo | R. Diaz | R. Kelishadi | Rajeev Gupta | K. Teo | A. Rosengren | O. Rahman | S. Rangarajan | K. Alhabib | F. Lanas | A. Avezum | J. Chifamba | K. Yeates | K. Zatońska | D. Leong | P. Mony | K. Vijayakumar | K. Kazmi | Viswanathan Mohan | A. Wielgosz | A. Yusufali | Noorhassim Ismail | R. Khatib | P. Joseph | Koon K Teo | Karen Yeates | Darryl P Leong | Sumathy Rangarajan | Alvaro Avezum | Annika Rosengren | Katarzyna Zatonska | Jephat Chifamba | Viswanathan Mohan | Gilles R Dagenais | Rafael Diaz | A. Temizhan | Khalid F Alhabib | Ahmet Temizhan | Khawar Kazmi | Li Wei | Rasha Khatib | Gustavo B F Oliveira | Shameena R Parambath | Noorhassim Ismail | K Vijayakumar | Manmeet Kaur | AfzalHussein Yusufali | Philip Joseph | G. Oliveira | Manmeet Kaur | Li Wei | Li Wei | K. Vijayakumar | G.B.D.F. Oliveira | Á. Avezum | V. Mohan | Krishnapillai Vijayakumar
[1] M. Brauer,et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study , 2020, The Lancet.
[2] F. Bray,et al. Effect on longevity of one-third reduction in premature mortality from non-communicable diseases by 2030: a global analysis of the Sustainable Development Goal health target. , 2018, The Lancet. Global health.
[3] M. Cullen,et al. Socioeconomic Differences in the Epidemiologic Transition From Heart Disease to Cancer as the Leading Cause of Death in the United States, 2003 to 2015 , 2018, Annals of Internal Medicine.
[4] Mohammad Hossein Khosravi,et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.
[5] M. Kruk,et al. Mortality due to low-quality health systems in the universal health coverage era: a systematic analysis of amenable deaths in 137 countries , 2018, The Lancet.
[6] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[7] T. Driscoll,et al. Incidence, prevalence, mortality, disability-adjusted life years and risk factors of cancer in Australia and comparison with OECD countries, 1990-2015: findings from the Global Burden of Disease Study 2015. , 2018, Cancer epidemiology.
[8] S. Yusuf,et al. Prognostic validation of a non-laboratory and a laboratory based cardiovascular disease risk score in multiple regions of the world , 2017, Heart.
[9] Dan J Stein,et al. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017, Lancet.
[10] S. Yusuf,et al. Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease , 2017, Circulation research.
[11] S. Yusuf,et al. Reducing the Global Burden of Cardiovascular Disease, Part 1: The Epidemiology and Risk Factors. , 2017, Circulation research.
[12] Alan D. Lopez,et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015 , 2017, Journal of the American College of Cardiology.
[13] Martin McKee,et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. , 2014, The New England journal of medicine.
[14] V. Feigin,et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010 , 2014, The Lancet.
[15] P. Byass,et al. The development and experience of epidemiological transition theory over four decades: a systematic review. , 2014, Global health action.
[16] S. Yusuf,et al. Prospective Urban Rural Epidemiology (PURE) study: Baseline characteristics of the household sample and comparative analyses with national data in 17 countries. , 2013, American heart journal.
[17] Martin McKee,et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. , 2013, JAMA.
[18] K. Lindblade,et al. Putting surveillance data into context: The role of health care utilization surveys in understanding population burden of pneumonia in developing countries , 2012, Journal of Epidemiology and Global Health.
[19] S. Yusuf,et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey , 2011, The Lancet.
[20] S. Yusuf,et al. Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. , 2011, European heart journal.
[21] Salim Yusuf,et al. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. , 2009, American heart journal.
[22] Simon Capewell,et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. , 2007, The New England journal of medicine.
[23] S. Yusuf,et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.
[24] H. Tunstall-Pedoe,et al. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations , 2000, The Lancet.